Myasthenia gravis affects about 30 out of every 100,000 people in Canada, according to the Myasthenia Gravis Society of ...

UCB, a global biopharmaceutical company, today announced the recipients of its annual UCB Myasthenia Gravis Scholarship,™ awarding 15 scholarships to individuals in the United States who are living ...

Life with myasthenia gravis (MG) means managing fluctuating muscle weakness and fatigue that can change by the hour. This can make it difficult — and sometimes even dangerous — to perform daily tasks ...

Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...

Tempest's TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage ...

New analyses from the Phase 3 Vivacity-MG3 study support the impact of nipocalimab in anti-AChR+a, anti-MuSK+b adult patients with generalised myasthenia gravis (gMG) including those early in their ...

Johnson & Johnson (NYSE: JNJ) today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY® ...

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target ...

Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.

Vyvgart is used to treat generalized myasthenia gravis (MG) in adults. Vyvgart is given as an intravenous (IV) infusion by a healthcare professional, typically in 4-week treatment cycles with one dose ...

UCB S.A. UCBJY UCBJF on Wednesday presented new data at the International Congress on Neuromuscular Diseases 2026 showing that long-term treatment with rozanolixizumab and zilucoplan delivered ...